Form 4: Intuitive Surgical CEO's Routine Equity Transactions

Intuitive Surgical CEO David J. Rosa reported the vesting and exercise of restricted stock units and the achievement of performance criteria for performance stock units, alongside tax-related share dispositions.

Summary

• CEO David J. Rosa acquired 3,816 shares of common stock through the exercise/conversion of Restricted Stock Units (RSUs) on February 26, 2026.
• Concurrently, 1,892 shares of common stock were disposed of at $506.17 per share to cover statutory tax withholding requirements related to the RSU vesting.
• An additional 2,289 shares of common stock were acquired through the exercise/conversion of RSUs on February 26, 2026.
• 1,135 shares of common stock were disposed of at $506.17 per share to cover statutory tax withholding requirements for this subsequent RSU vesting event.
• Performance criteria for 4,788 Performance Stock Units (PSUs) initially granted on February 28, 2023, were achieved, with these PSUs scheduled to vest on February 28, 2026.
• Performance criteria for 3,018 PSUs initially granted on June 12, 2023, were also achieved, with these PSUs scheduled to vest on February 28, 2026.
• A new grant of 13,441 Restricted Stock Units was issued to David J. Rosa on February 26, 2026, which will vest 25% annually over a four-year period.
• Following these transactions, David J. Rosa directly beneficially owns 232,648 shares of Intuitive Surgical common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, primarily due to the achievement of performance criteria for PSUs, indicating successful execution against company goals, and the continued alignment of CEO incentives with long-term value through new equity grants.

Positives

• Performance criteria for 4,788 PSUs (granted 2/28/2023) and 3,018 PSUs (granted 6/12/2023) were achieved, indicating successful execution against company-defined metrics.
• CEO David J. Rosa acquired a net of 3,078 shares of common stock through RSU vesting (6,105 shares acquired minus 3,027 shares disposed for tax), increasing his direct beneficial ownership.
• A new grant of 13,441 Restricted Stock Units was issued to the CEO on February 26, 2026, reinforcing alignment of executive incentives with long-term shareholder value.

Negatives

• A total of 3,027 shares of common stock were disposed of at $506.17 per share to cover statutory tax withholding requirements, reducing the immediate increase in direct beneficial ownership from RSU vesting.

Future Outlook

The vesting of Performance Stock Units on February 28, 2026, is contingent upon David J. Rosa's continuous service to Intuitive Surgical through that date. New Restricted Stock Units granted on February 26, 2026, will vest 25% annually over a four-year period, aligning future compensation with long-term company performance.

Industry Context

StockSavvy.ai notes that the reported transactions reflect routine executive equity compensation practices, common across the medical device and technology sectors. The achievement of performance metrics for PSUs indicates that Intuitive Surgical met specific operational or financial targets, a positive signal for investors regarding management's execution against pre-defined goals. The structure of RSU and PSU grants is a standard mechanism to align executive incentives with long-term shareholder value creation and retention.

Comparison to Industry Standards

• The equity compensation structure, involving both Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) with multi-year vesting schedules, is consistent with best practices observed in leading medical technology companies such as Medtronic plc (MDT) and Johnson & Johnson (JNJ).
• The use of PSUs tied to specific performance metrics, as seen with the achieved criteria for David J. Rosa's grants, is a common approach to incentivize executives for achieving strategic objectives, similar to how Stryker Corporation (SYK) structures a portion of its executive long-term incentives.
• The disposition of shares to cover tax obligations upon vesting is a standard, non-discretionary event in equity compensation plans across the industry.

Stakeholder Impact

• Shareholders: Positive impact from the achievement of performance metrics, suggesting operational success. Routine equity vesting and tax-related sales are generally neutral, but new grants align management with long-term shareholder interests.
• Employees: No direct impact mentioned, but successful performance metrics could indirectly boost morale or future compensation pools.

Next Steps

• Vesting of Performance Stock Units on February 28, 2026, subject to continuous service.
• Annual vesting of new Restricted Stock Units (granted 2/26/2026) over a four-year period.

Key Dates

Recommendation

This Form 4 details routine, pre-scheduled equity compensation events for the CEO, including the vesting of stock units and associated tax-related share dispositions. While the achievement of performance metrics for PSUs is a positive signal regarding company execution, these transactions are largely expected and do not introduce new material information that would significantly alter the investment thesis for Intuitive Surgical. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than these specific insider transactions.

Keywords

Intuitive Surgical, ISRG, David J. Rosa, CEO, Form 4, Insider Transaction, Restricted Stock Units, Performance Stock Units, Equity Compensation, Stock Vesting, Tax Withholding